Rocket Pharmaceuticals, Inc. CEO Gaurav Shah disclosed the sale of 2,837 shares of common stock valued at approximately $7,752 on August 13, 2026. Reported via an SEC Form 4 filing submitted on August 17, 2026, the transaction was executed strictly to fulfill mandatory tax withholding obligations tied to the vesting of restricted stock units.
Financial disclosures of this nature provide insight into corporate governance structures, executive equity retention, and regulatory reporting requirements governed by the United States Securities and Exchange Commission (SEC).
In Plain English: The Clinical Takeaway
- Executive Equity Management: Stock sales tied to restricted stock units (RSUs) are routine administrative transactions designed to cover personal income tax obligations when equity awards vest.
- Ownership Stakes Maintained: Following the August 13 transaction, CEO Gaurav Shah retained a direct beneficial ownership of 1,058,887 shares in Rocket Pharmaceuticals.
- Indirect Holdings: Additional holdings include 207,897 shares held indirectly by his spouse and 198,341 shares held by the Gaurav D. Shah Irrevocable Trust, reflecting continued alignment with company milestones.
Financial Disclosure Mechanics and Form 4 Filings
According to regulatory disclosures analyzed from financial reporting sources, Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) executive Gaurav Shah executed the sale of 2,837 shares at a transaction price of $3.381 per share. The Form 4 filing indicates that the transaction was coded with an “S” for sale and classified as a direct disposal under standard regulatory instructions. Martin Wilson signed the document as attorney-in-fact for Shah on August 17, 2026.
Such transactions are standard operating procedure for corporate officers managing equity-based compensation. When restricted stock units vest, they are treated as taxable income under Internal Revenue Service (IRS) guidelines. To satisfy these tax liabilities, companies or executives frequently utilize “sell-to-cover” transactions, wherein a designated portion of the newly vested shares is automatically or manually sold on the open market.
Comparative Overview of Reported Holdings
| Holding Category | Shares / Details | Transaction Purpose |
|---|---|---|
| Direct Ownership (Post-Sale) | 1,058,887 shares (includes RSUs convertible one-for-one) | Retained equity following tax-driven disposal |
| Executed Transaction | 2,837 common shares at $3.381 per share | Fulfill RSU tax withholding requirements on August 13, 2026 |
| Indirect Holdings (Spouse) | 207,897 shares | Beneficial ownership via family holdings |
| Indirect Holdings (Trust) | 198,341 shares | Held via the Gaurav D. Shah Irrevocable Trust |
This financial reporting coincides with broader corporate updates from Rocket Pharmaceuticals, including the company’s 2026 Annual Meeting of Stockholders, where approximately 74.02% of the company’s outstanding common stock was represented. Transparent reporting of insider transactions ensures adherence to federal securities laws and provides public markets with clear visibility into executive stake management.
Contraindications & When to Consult a Doctor
Patients or clinical trial participants monitoring biotechnology developments should not interpret corporate equity disclosures as indicators of therapeutic efficacy, safety profiles, or regulatory approvals. For medical advice regarding specific health conditions, genetic disorders, or clinical trial enrollment opportunities, individuals must consult qualified healthcare professionals, primary care physicians, or board-certified specialists.
If you experience acute medical symptoms, adverse reactions to prescribed medications, or unexpected changes in your health status, seek immediate evaluation at a licensed medical facility or contact emergency services. Never alter prescribed treatment regimens or participation in clinical studies without direct supervision from your attending physician or principal investigator.
References
- U.S. Securities and Exchange Commission (SEC). Form 4 Filing: Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). Filed August 17, 2026.
- Kalkine Media. “Rocket Pharmaceuticals CEO Gaurav Shah Sells 2,837 Shares to Cover RSU Tax Withholding.” August 2026.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial, investment, or medical advice. Readers should conduct independent due diligence and consult certified financial advisors or healthcare professionals before making investment or health-related decisions.
